Huiyu Pharmaceutical(688553)2025-01-24 12:25Revenue Projections - The company expects 2024 annual revenue to be between 1,070 million and 1,130 million CNY, representing a year-on-year growth of 15.42% to 21.89%[4]. - The projected net profit attributable to the parent company for 2024 is expected to be between 300 million and 360 million CNY, indicating a year-on-year increase of 114.61% to 157.54%[4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is anticipated to be between 95 million and 110 million CNY, reflecting a year-on-year growth of 43.92% to 66.64%[4]. Market Performance - International market business increased by approximately 90 million CNY, a growth of 103% compared to the previous year[8]. - Domestic product sales, including Plasmapheresis Injection and others, increased by approximately 92 million CNY, a growth of 11% compared to the previous year[8]. Investment and Financial Impact - The company recognized a fair value change gain of 211 million CNY from its investment in Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which is set to be listed on the Hong Kong Stock Exchange[8]. - The company's financial performance may be significantly impacted by the stock price fluctuations of its invested enterprise, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd.[8]. Financial Reporting and Uncertainties - The financial data in this earnings forecast has not been audited by a registered accountant and is based on preliminary calculations by the finance department[5]. - The company has not identified any major uncertainties affecting the accuracy of this earnings forecast as of the announcement date[9]. - The final and accurate financial data will be disclosed in the audited annual report for 2024[11].